Compare IDEXX Laboratories, Inc. (IDXX) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? IDEXX Laboratories, Inc. trades at $556.84 (market cap $44.48B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.67. Which is the better fit depends on your goals.
| IDXX | YMAG | |
|---|---|---|
Market Cap | $44.48B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $766.68 | $15.98 |
52-Week Low | $520.87 | $11.00 |
Enterprise Value | $45.38B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
YMAG trades at $11.63, up 0.17% with a neutral technical signal. The ETF provides weekly dividend distributions, recently ranging from $0.07 to $0.40 per share. Key financial ratios are unavailable, but the fund's strategy focuses on option income from Magnificent Seven stocks. Recent news highlights consistent distribution announcements and tactical performance discussions.
Outlook hinges on option income strategy effectiveness in volatile markets. Opportunities include high yield potential, but risks involve NAV decay and expense ratio drag. Investor sentiment is mixed, with some analysts citing underperformance versus benchmarks amid low implied volatility reducing yield potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
